@article{3078115,
    title = "Genotyping KRAS and EGFR mutations in Greek patients with non-small-cell lung cancer: Incidence, significance and implications for treatment",
    author = "Linardou, H. and Kotoula, V. and Kouvatseas, G. and Mountzios, G. and Karavasilis, V. and Samantas, E. and Kalogera-Fountzila, A. and Televantou, D. and Papadopoulou, K. and Mavropoulou, X. and Daskalaki, E. and Zaramboukas, T. and Efstratiou, I. and Lampaki, S. and Rallis, G. and Res, E. and Syrigos, K.N. and Kosmidis, P.A. and Pectasides, D. and Fountzilas, G.",
    journal = "Cancer Genomics and Proteomics",
    year = "2019",
    volume = "16",
    number = "6",
    pages = "531-541",
    publisher = "International Institute of Anticancer Research",
    doi = "10.21873/CGP.20154",
    keywords = "epidermal growth factor receptor;  K ras protein;  EGFR protein, human;  epidermal growth factor receptor;  KRAS protein, human;  protein p21, adult;  aged;  Article;  cancer incidence;  cancer therapy;  controlled study;  current smoker;  female;  follow up;  gene mutation;  genotype;  Greece;  human;  human tissue;  lung adenocarcinoma;  major clinical study;  male;  non small cell lung cancer;  overall survival;  retrospective study;  clinical trial;  disease free survival;  genetics;  genotyping technique;  lung tumor;  middle aged;  mortality;  mutation;  non small cell lung cancer;  survival rate;  very elderly, Adult;  Aged;  Aged, 80 and over;  Carcinoma, Non-Small-Cell Lung;  Disease-Free Survival;  ErbB Receptors;  Female;  Follow-Up Studies;  Genotyping Techniques;  Humans;  Lung Neoplasms;  Male;  Middle Aged;  Mutation;  Proto-Oncogene Proteins p21(ras);  Retrospective Studies;  Survival Rate",
    abstract = "Background/Aim: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLC patients. Patients and Methods: KRAS and EGFR genotypes were centrally evaluated in 421 NSCLC patients (diagnosed September 1998 -June 2013) and associated with clinicopathological parameters. Outcome comparisons were performed in 288 patients receiving first line treatment. Results: Most patients were male (78.6%), >60 years old (63.9%), current smokers (51.1%), with adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in 10.7% and 16.6% of all histologies, respectively, and in 14.9% and 21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status was an independent negative prognostic factor for overall survival (OS, p=0.016). KRAS mutations conferred 80% increased risk of death in patients receiving first-line treatment (p=0.002). Conclusion: The presence of KRAS mutations is an independent negative prognosticator among Greek NSCLC patients and an independent response predictor to first line treatment. © 2019 International Institute of Anticancer Research. All rights reserved."
}